Moreover, there are recently developed inhibitors of BTK, such as ibrutinib (PC1–32765), AVL-292, and CGI-1746, which prevent drug-resistant clones from arising and reduce BC cell survival [61–64]. This evidence concerns the gene BTK and breast cancer.